|
|
Article: DEPRENYL ANIMAL HEALTH, INC. REPORTS PRELIMINARY POSITIVE RESULTS IN USE OF ANIPRYL FOR TREATING COGNITIVE DYSFUNCTION (DEMENTIA) IN PET DOGS
- Article from:
- PR Newswire
- Article date:
- January 14, 1993
CopyrightCOPYRIGHT 1993 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
OVERLAND PARK, Kan., Jan. 14 /PRNewswire/ -- Deprenyl Animal Health, Inc. (NASDAQ: DAHI; Toronto Stock Exchange: DAH) reported today it has achieved positive interim results in a continuing clinical trial of Anipryl(R) for the treatment of cognitive dysfunction (dementia) in pet dogs. The company announced in July 1992 that it had received a U.S. patent covering the use of Anipryl (I-deprenyl) to treat this affliction of dogs.
According to David R. Stevens, president and CEO, "These initial one month clinical trial results on the first 18 pet dogs are quite encouraging. Many of the aging pet dogs enrolled in this program have demonstrated significant clinical improvement ...